Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.

摘要: Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies under development. We sought to describe treatment outcomes and genomic immunophenotypic characteristics of these tumors. Experimental Design: identified sequential patients with NSCLC ex20ins compared their clinical pathologic features other NSCLC. Results: Among 6,290 NSCLC, 106 (2%) had ex20ins. Patients were more likely be Black (14% vs. 6%; P Conclusions: With better on platinum chemotherapy, have improved prognosis, lower PD-L1 expression TMB, derive less benefit from ICIs without targetable oncogenes. Improving molecularly could provide greater